CoChat

Ecological vaccination: A strategy to prevent zoonotic spillover from bats

Open access
Li, Hongyue, Yuan, Fei, Yao, Yanfeng, Wang, Jinglin, Li, Chunzheng, Liu, Ye, Yang, Jinmei, Zhang, Zhongyang, Liu, Jiandong, Liu, Jiankai, Yang, Zhenxing, Jin, Wanzhu, Wen, Dan, Shan, Chao, Zheng, Aihua · 2026 · Science Advances

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index; 1 of the 33 sources its claims cite were checked for support.

Abstract

Bats serve as critical reservoirs of zoonotic pathogens but also play essential ecological roles. To mitigate spillover risks without harming bat populations, we developed a multiroute vaccination strategy using recombinant vesicular stomatitis virus (rVSV)–based vaccines. Vaccine-carrying mosquitoes delivered rVSV-based rabies and Nipah vaccines, conferring protection in rodent and bat models. Under simulated natural conditions, cohabitation with vaccine-carrying mosquitoes elicited strong immune responses in bats, supporting feasibility beyond laboratory settings. As a complementary approach, saline traps exploiting bats’ mineral-seeking behavior achieved comparable immune protection through oral vaccination. Together, these results demonstrate a flexible, ecology-informed vaccination platform for immunizing wild bats, offering a scalable strategy to reduce zoonotic spillover risk while supporting bat conservation.

Overview

CoChat Summary

TL;DR

The paper develops an “ecological vaccination” platform that uses recombinant VSV vaccines delivered either by mosquitoes or by saline traps to immunize bats against rabies and Nipah virus. In laboratory and field-simulation experiments, the strategies induced neutralizing antibodies and protected mice, hamsters, and bats from lethal challenge or seroconversion against the target viruses.

Key findings

  • rVSV-RABV and rVSV-NiV were successfully constructed and amplified in Vero cells, reaching titers of 10^8 FFU/ml for rVSV-RABV and 10^7 FFU/ml for rVSV-NiV.
  • Mosquito-delivered rVSV-RABV protected mice: after ingestion of vaccine-carrying mosquitoes, VNA GMTs reached 4.6 and 6.8 IU/ml by day 14 and survival after rabies challenge was 91.6% (5 mosquitoes) and 100% (20 mosquitoes); the mosquito-bite group had 58% survival.
  • In greater tube-nosed bats, mosquito-bite delivery of rVSV-RABV led all bats in that group to exceed 0.5 IU/ml after the booster, and survival after rabies challenge was 100% in the bite group and 75% in the ingestion group.
  • Oral rVSV-RABV protected mice and bats: mice given 10^6 or 10^7 FFU developed VNA titers of 2.37/3.24 IU/ml and 5.31/12.16 IU/ml at days 14/28, and all vaccinated mice survived challenge; in bats, a two-dose regimen raised VNA GMTs to 1.3 IU/ml and all 4 vaccinated bats survived rabies challenge, including a second challenge 3 months later.
  • For NiV, two mosquito bites or a single oral dose of rVSV-NiV elicited high neutralizing antibody levels in hamsters (GMT 553.4 after bites; 172 on day 14 and 2406 on day 28 after oral dosing) and all vaccinated hamsters survived lethal challenge with either the Malaysia or Bangladesh strain.
  • Field-simulation data supported feasibility: in a Guangdong cave, bat fecal metabarcoding showed insects including Culicidae, and mosquito blood meals contained genetic material from Rhinolophidae (bats); a saline trap with tetracycline yielded tetracycline in 85% of fresh bat fecal samples after 1 week, indicating uptake.

Methods

  • The study constructed recombinant vesicular stomatitis viruses encoding rabies virus G, Nipah virus G, and a SARS-CoV antigen, then characterized growth and protein expression in cell culture before testing delivery in mosquitoes and oral saline formulations.
  • Animal experiments used BALB/c mice, golden Syrian hamsters, Bama miniature pigs, and wild-caught bats (M. leucogaster and R. ferrumequinum), with mosquito ingestion, mosquito-bite, and oral dosing regimens followed by neutralization assays and lethal viral challenges.
  • Field-simulation and ecological feasibility tests included bat-mosquito interaction sampling in a Guangdong cave, tetracycline biomarker detection in bat feces, and observation of bat drinking behavior from a saline trap in an enclosed space.

Limitations

  • The paper states that it could not directly assess Nipah virus challenge protection in bats.
  • The study used booster regimens and says future work should optimize single-dose formulations.
  • Evident from the text: bat cohorts were small, with four bats per cohort in experiments and six bats in field simulations, which limits inference about field-scale effectiveness.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.aec0269

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Fig. 1. Characterization of rVSV-RABV and its propagation in Ae. aegypti. (A) Schematic diagram of rVSV-RABV, which was engineered by inserting the open reading frame of the RABV G gene (RVG) between the VSV matrix (M) and glycoprotein (G) genes in the vector. (B) Growth kinetics of rVSV-RABV and rVSV in Vero cells. (C) Western blot analysis of purified rVSV-RABV and rVSV from supernatants, probed with an antibody against RABV G protein. (D) Schematic illustration of mosquito infection via blood feeding with either rVSV-RABV or rVSV. Viral titers in whole mosquitoes (E) and salivary glands (F) were assessed at indicated days post–blood feeding by focus-forming assay. Error bars indicate SD of the mean. Statistical significance was determined using the unpaired two-tailed Student’s t test. Above data are representatives of three independent experiments. n.s., not significant.
Fig. 1. Characterization of rVSV-RABV and its propagation in Ae. aegypti. (A) Schematic diagram of rVSV-RABV, which was engineered by inserting the open reading frame of the RABV G gene (RVG) between the VSV matrix (M) and glycoprotein (G) genes in the vector. (B) Growth kinetics of rVSV-RABV and rVSV in Vero cells. (C) Western blot analysis of purified rVSV-RABV and rVSV from supernatants, probed with an antibody against RABV G protein. (D) Schematic illustration of mosquito infection via blood feeding with either rVSV-RABV or rVSV. Viral titers in whole mosquitoes (E) and salivary glands (F) were assessed at indicated days post–blood feeding by focus-forming assay. Error bars indicate SD of the mean. Statistical significance was determined using the unpaired two-tailed Student’s t test. Above data are representatives of three independent experiments. n.s., not significant.CC BY · PubMed Central
Fig. 2. Mosquito-mediated rVSV-RABV vaccination protects mice from RABV challenge. (A) Schematic of experimental design of mouse vaccination and challenge studies. Groups of female BALB/c mice (n = 12) were vaccinated with rVSV-RABV–carrying mosquitoes either via ingestion (one dose) or bites (two doses). Nonvaccinated mice served as controls (Con.). (B) Body weight changes of mice monitored daily for 7 days following the first vaccination. Error bars indicate SD of the mean. (C) RABV-neutralizing antibody (VNA) titers in mice vaccinated via ingestion were measured at 14 and 28 days postvaccination in mice orally fed with mosquito homogenates (5 or 20 mosquitoes) using the FAVN test. (D) VNA titers in mice vaccinated via bites, i.e., exposed to two mosquito feeding events (30 mosquitoes per exposure) over 4 weeks, at 28 and 42 days post–initial exposure. Above data are representatives of three independent experiments. (E) Vaccinated mice were intracerebrally challenged with the RABV CVS-11 strain, and survival was monitored for 14 days.
Fig. 2. Mosquito-mediated rVSV-RABV vaccination protects mice from RABV challenge. (A) Schematic of experimental design of mouse vaccination and challenge studies. Groups of female BALB/c mice (n = 12) were vaccinated with rVSV-RABV–carrying mosquitoes either via ingestion (one dose) or bites (two doses). Nonvaccinated mice served as controls (Con.). (B) Body weight changes of mice monitored daily for 7 days following the first vaccination. Error bars indicate SD of the mean. (C) RABV-neutralizing antibody (VNA) titers in mice vaccinated via ingestion were measured at 14 and 28 days postvaccination in mice orally fed with mosquito homogenates (5 or 20 mosquitoes) using the FAVN test. (D) VNA titers in mice vaccinated via bites, i.e., exposed to two mosquito feeding events (30 mosquitoes per exposure) over 4 weeks, at 28 and 42 days post–initial exposure. Above data are representatives of three independent experiments. (E) Vaccinated mice were intracerebrally challenged with the RABV CVS-11 strain, and survival was monitored for 14 days.CC BY · PubMed Central
Fig. 3. Mosquito-mediated rVSV-RABV vaccination protects bats from RABV challenge. (A) Schematic of the experimental design of vaccination and challenge in bats. Groups of bats (n = 4) were vaccinated with two doses of rVSV-RABV–carrying mosquitoes, either via ingestion (homogenates from 20 mosquitoes) or bites (30 mosquitoes per dose). Nonvaccinated bats served as controls (Con.). (B) Body weight changes of bats monitored for 10 days following the first vaccination. (C) RABV-neutralizing antibody (VNA) titers in bats measured at 42 days postvaccination. (D to F) Bats were intracranially challenged with 1000 MICLD50 of the RABV CVS-11 strain at 42 days postvaccination. Body weight changes (D) and survival rates (E) were monitored for 30 days following the challenge. (F) Viral RNA loads in brain tissue quantified by qRT-PCR at 30 days postchallenge. Dotted lines in (F) indicate the detection limit of the assay. Error bars in (B) and (D) indicate SD of the mean.
Fig. 3. Mosquito-mediated rVSV-RABV vaccination protects bats from RABV challenge. (A) Schematic of the experimental design of vaccination and challenge in bats. Groups of bats (n = 4) were vaccinated with two doses of rVSV-RABV–carrying mosquitoes, either via ingestion (homogenates from 20 mosquitoes) or bites (30 mosquitoes per dose). Nonvaccinated bats served as controls (Con.). (B) Body weight changes of bats monitored for 10 days following the first vaccination. (C) RABV-neutralizing antibody (VNA) titers in bats measured at 42 days postvaccination. (D to F) Bats were intracranially challenged with 1000 MICLD50 of the RABV CVS-11 strain at 42 days postvaccination. Body weight changes (D) and survival rates (E) were monitored for 30 days following the challenge. (F) Viral RNA loads in brain tissue quantified by qRT-PCR at 30 days postchallenge. Dotted lines in (F) indicate the detection limit of the assay. Error bars in (B) and (D) indicate SD of the mean.CC BY · PubMed Central
Fig. 4. Protective immunity following oral rVSV-RABV vaccination in mice and bats. (A) Schematic of experimental design of the vaccination and challenge protocols for mice. (B to D) Female BALB/c mice (n = 12) received a single oral dose of rVSV-RABV (106 or 107 FFU per animal). Mice fed with PBS served as controls (Con.). (B) VNA titers measured at 14 and 28 days postvaccination using the FAVN test. (C) Long-term VNA levels tracked over 6 months. (D) Mice were intracerebrally challenged with 50 LD50 of the RABV CVS-11 strain, and survival rates were recorded for 14 days. Above data are representatives of three independent experiments. (E) Schematic of experimental design of the vaccination and challenge protocols for bats. (F to J) Bats (n = 4) were orally vaccinated with two doses of rVSV-RABV (107 FFU per animal). Bats fed with PBS served as controls (Con.). (F) VNA titers in bats measured at 28 and 42 days postvaccination. [(G) to (H)] Bats were intracranially challenged with 1000 MICLD50 of the RABV CVS-11 strain. Body weight (G) and survival rates (H) monitored for 30 days postchallenge. [(I) and (J)] A secondary challenge in bats was conducted 3 months after the primary challenge. (I) Body weight changes following the second challenge. (J) Survival rates recorded for 30 days post–secondary challenge. Error bars in (G) and (I) indicate SD of the mean.
Fig. 4. Protective immunity following oral rVSV-RABV vaccination in mice and bats. (A) Schematic of experimental design of the vaccination and challenge protocols for mice. (B to D) Female BALB/c mice (n = 12) received a single oral dose of rVSV-RABV (106 or 107 FFU per animal). Mice fed with PBS served as controls (Con.). (B) VNA titers measured at 14 and 28 days postvaccination using the FAVN test. (C) Long-term VNA levels tracked over 6 months. (D) Mice were intracerebrally challenged with 50 LD50 of the RABV CVS-11 strain, and survival rates were recorded for 14 days. Above data are representatives of three independent experiments. (E) Schematic of experimental design of the vaccination and challenge protocols for bats. (F to J) Bats (n = 4) were orally vaccinated with two doses of rVSV-RABV (107 FFU per animal). Bats fed with PBS served as controls (Con.). (F) VNA titers in bats measured at 28 and 42 days postvaccination. [(G) to (H)] Bats were intracranially challenged with 1000 MICLD50 of the RABV CVS-11 strain. Body weight (G) and survival rates (H) monitored for 30 days postchallenge. [(I) and (J)] A secondary challenge in bats was conducted 3 months after the primary challenge. (I) Body weight changes following the second challenge. (J) Survival rates recorded for 30 days post–secondary challenge. Error bars in (G) and (I) indicate SD of the mean.CC BY · PubMed Central
Fig. 5. Efficacy of the rVSV-NiV vaccine in hamsters and bats. (A) Schematic representation of the experimental design of the vaccination and challenge protocols for golden Syrian hamsters. (B) Hamsters (n = 12) were exposed twice, at a 4-week interval, to bites from rVSV-NiV–carrying mosquitoes (30 mosquitoes per animal), or were orally given a single dose of rVSV-NiV (106 FFU). Neutralizing antibody (NAb) titers against rVSVΔG-eGFP-NiV F/G were measured at indicated days postvaccination using the focus reduction neutralization test (FRNT). (C and D) Vaccinated and control hamsters were intraperitoneally challenged with 1000 LD50 of NiV (Malaysia or Bangladesh strain). Survival rates were monitored daily for 21 days. Nonvaccinated hamsters served as controls (Con.) (E) Schematic representation of the experimental design of the vaccination protocols for bats. (F) Bats (n = 4) were vaccinated either by exposure to bites from rVSV-NiV–carrying mosquitoes (30 mosquitoes per bat) or by oral administration of rVSV-NiV on two occasions, with an interval of 4 weeks. NAb titers were measured as described in (B). Control bats were nonvaccinated (Con.).
Fig. 5. Efficacy of the rVSV-NiV vaccine in hamsters and bats. (A) Schematic representation of the experimental design of the vaccination and challenge protocols for golden Syrian hamsters. (B) Hamsters (n = 12) were exposed twice, at a 4-week interval, to bites from rVSV-NiV–carrying mosquitoes (30 mosquitoes per animal), or were orally given a single dose of rVSV-NiV (106 FFU). Neutralizing antibody (NAb) titers against rVSVΔG-eGFP-NiV F/G were measured at indicated days postvaccination using the focus reduction neutralization test (FRNT). (C and D) Vaccinated and control hamsters were intraperitoneally challenged with 1000 LD50 of NiV (Malaysia or Bangladesh strain). Survival rates were monitored daily for 21 days. Nonvaccinated hamsters served as controls (Con.) (E) Schematic representation of the experimental design of the vaccination protocols for bats. (F) Bats (n = 4) were vaccinated either by exposure to bites from rVSV-NiV–carrying mosquitoes (30 mosquitoes per bat) or by oral administration of rVSV-NiV on two occasions, with an interval of 4 weeks. NAb titers were measured as described in (B). Control bats were nonvaccinated (Con.).CC BY · PubMed Central
Fig. 6. Bat behavior in the field and bat immunization under simulated field conditions. (A) Dietary composition of bats (H. larvatus) (left) and mosquitoes (A. subalbatus) (right) from the same cave in Guangdong province, categorized at the family level using DNA metabarcoding. Data are presented as relative read abundance with different colors representing distinct taxa. (B) Six bats were exposed to 300 rVSV-RABV–carrying mosquitoes in a controlled laboratory setting for 48 hours. VNA titers in bats were measured at 0, 14, and 28 days postexposure using the FAVN method. (C) Illustration of the saline trap design, comprising a container holding a mixture of vaccine and saline alongside a salt-mist generator. (D) The field study site in Beijing, China, is indicated by the yellow circle (left). Surveillance footage shows two wild bats (arrows) drinking from a saline trap placed in the mineral cave (right). (E) Detection of tetracycline residues in bat feces by liquid chromatography–tandem mass spectrometry. A saline trap containing tetracycline was deployed in a mineral cave for 1 week. Fresh bat feces were subsequently collected and analyzed for tetracycline residues (Post). Bat feces collected before experiments were set as negative control (Pre). (F) rVSV and rVSV-RABV were incubated at 25°C for 28 days, and viral titers were measured by focus-forming assay and expressed as focus-forming units (FFU)/mL. These data are representative of three independent experiments. (G) The saline trap containing rVSV-SARS vaccine was placed in a room with six free bats. NAb titers against rVSVΔG-eGFP-SARS were measured at 0, 14, and 28 days postvaccination using the FRNT. Dotted lines in (G) indicate the detection limit of the assay. LOD, limit of detection.
Fig. 6. Bat behavior in the field and bat immunization under simulated field conditions. (A) Dietary composition of bats (H. larvatus) (left) and mosquitoes (A. subalbatus) (right) from the same cave in Guangdong province, categorized at the family level using DNA metabarcoding. Data are presented as relative read abundance with different colors representing distinct taxa. (B) Six bats were exposed to 300 rVSV-RABV–carrying mosquitoes in a controlled laboratory setting for 48 hours. VNA titers in bats were measured at 0, 14, and 28 days postexposure using the FAVN method. (C) Illustration of the saline trap design, comprising a container holding a mixture of vaccine and saline alongside a salt-mist generator. (D) The field study site in Beijing, China, is indicated by the yellow circle (left). Surveillance footage shows two wild bats (arrows) drinking from a saline trap placed in the mineral cave (right). (E) Detection of tetracycline residues in bat feces by liquid chromatography–tandem mass spectrometry. A saline trap containing tetracycline was deployed in a mineral cave for 1 week. Fresh bat feces were subsequently collected and analyzed for tetracycline residues (Post). Bat feces collected before experiments were set as negative control (Pre). (F) rVSV and rVSV-RABV were incubated at 25°C for 28 days, and viral titers were measured by focus-forming assay and expressed as focus-forming units (FFU)/mL. These data are representative of three independent experiments. (G) The saline trap containing rVSV-SARS vaccine was placed in a room with six free bats. NAb titers against rVSVΔG-eGFP-SARS were measured at 0, 14, and 28 days postvaccination using the FRNT. Dotted lines in (G) indicate the detection limit of the assay. LOD, limit of detection.CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 12 Not checked · 47 Own results and interpretations

12 more claims

Create a free account to see all 60 claims and to verify the 32 references still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 49 references

Research works printed but not linked: 3

  1. D. G. Streicker, S. Recuenco, W. Valderrama, J. G. Benavides, I. Vargas, V. Pacheco, R. E. Condori Condori, J. Montgomery, C. E. Rupprecht, P. Rohani, S. Altizer, Ecological and anthropogenic drivers of rabies exposure in vampire bats: Implications for transmission and control. Proc. Biol. Sci. 279, 3384–3392 (2012).
  2. G. G. Turner, D. M. Reeder, J. T. H. Coleman, A five-year assessment of mortality and geographic spread of white-nose syndrome in north american bats, with a look at the future. Update of white-nose syndrome in bats. Bat Res. News 52, 13–27 (2011).
  3. V. Brack, V. Brack, J. O. Whitaker Jr., Foods of the Northern myotis, Myotis septentrionalis, from Missouri and Indiana, with notes on foraging. Acta Chiropt. 3, 203–210 (2001).

Metadata

Authors
Li, H., Yuan, F., Yao, Y., Wang, J., Li, C., Liu, Y., Yang, J., Zhang, Z., Liu, J., Liu, J., Yang, Z., Jin, W., Wen, D., Shan, C., & Zheng, A.
Affiliations
  • Chinese Academy of Sciences (CN)
  • Kunming Medical University (CN)
  • Jilin Heyuan Bioengineering Co. Ltd., Jilin 138000, China.
  • Beijing Minhai Biotechnology Co., Ltd. (China) (CN)
  • Yunnan Animal Science and Veterinary Institute (CN)
Corresponding author
  • Li, Hongyue
  • Yuan, Fei
  • Yao, Yanfeng
  • Shan, Chao
  • Zheng, Aihua
Venue
Science Advances
Published
2026-03-13
Volume
12
Issue
11
Pages
eaec0269-eaec0269
ISSN
2375-2548 (ISSN-L)
OpenAlex
W7135090677
Cited by
0
References
49
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
Funders
  • National Natural Science Foundation of China (U24A20363)
  • National Key Plan for Scientific Research and Development of China (2024YFC2607505)
  • Natural Science Foundation of Wuhan (No. 2024040701010066)
  • Initiative Scientific Research Program Institute of Zoology Chinese Academy of Sciences (2023IOZ0205)
  • Bingzhi Postdoctoral Special Support Program of Institute of Zoology Chinese Academy of Sciences (E455I21133)
  • Grade of China Postdoctoral Science Foundation (GZC20341710)
  • Hainan Institute of National Park HINP (ZDYF2023RDYL01, KY-24ZK02)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Zoonotic diseases and public health
  • Life Sciences › Immunology and Microbiology › Virology › Rabies epidemiology and control
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
zoonotic spillover, bats, rabies vaccine, recombinant vesicular stomatitis virus, oral immunization, bat conservation, reservoir hosts
MeSH terms
Animals, Chiroptera, Humans, Rabies, Vaccination, Viral Vaccines, Zoonoses, Nipah Virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.